Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statements of Operations and Comprehensive Income (Loss) [Abstract]
Net sales	$ 6,041,004	$ 9,906,581	$ 16,276,861	$ 21,878,509
Costs of sales	(4,349,594)	(6,521,478)	(11,097,572)	(14,165,652)
Gross profit	1,691,410	3,385,103	5,179,289	7,712,857
Selling expenses	(796,302)	(611,880)	(2,078,771)	(1,706,112)
Administrative expenses	(1,358,109)	(574,092)	(3,337,168)	(1,795,328)
Depreciation and amortization	(67,337)	(16,642)	(183,891)	(43,071)
(Loss) income from operations	(530,338)	2,182,489	(420,541)	4,168,346
Other (expense) income	(3,125)		40,210
Interest income	147,037	23,573	173,183	193,026
Interest credit (expense)	46,575	(316,422)	(207,860)	(1,058,291)
Amortization of discount on notes		(698,495)	(402,394)	(2,080,301)
(Loss) income before income taxes	(339,851)	1,191,145	(817,402)	1,222,780
Income tax benefit (expense)	26,907	(222,513)	(58,704)	(652,711)
Net (loss) income	(312,944)	968,632	(876,106)	570,069
Net loss attributable to non-controlling interest	(10,860)		(15,857)
Net (loss) income attributable to Tanke Biosciences Corporation	(302,084)	968,632	(860,249)	570,069
Net (loss) income	(312,944)	968,632	(876,106)	570,069
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	152,227	(101,883)	664,816	109,074
Comprehensive (loss) income	(160,717)	866,749	(211,290)	679,143
Comprehensive loss attributable to non-controlling interest	(1,944)		(3,464)
Comprehensive (loss) income attributable to Tanke Biosciences Corporation	$ (158,773)	$ 866,749	$ (207,826)	$ 679,143
(Loss) income per common share:
Basic and diluted	$ (0.02)	$ 0.07	$ (0.07)	$ 0.04
Weighted average number of common shares used in computation
Basic and diluted	13,324,083	13,324,083	13,324,083	13,324,083